Acadia Pharmaceuticals Appoints Allyson McMillan-Youngblood To Lead Rare Disease Commercial Strategy

Acadia Pharmaceuticals has appointed Allyson McMillan-Youngblood as Senior Vice President of its Rare Disease Franchise. In her new role, she will join the company’s commercial leadership team and focus on optimizing the performance of DAYBUE® while also strategizing for future rare disease product launches.

“We are delighted to welcome Allyson to Acadia. She brings a remarkable breadth of experience across U.S. and global sales and marketing roles, with a proven track record of delivering strong commercial results. Her leadership across therapeutic areas including oncology, immunology, CNS, infectious disease, cardiovascular and metabolic disorders as well as her experience specifically in rare oncology, will be invaluable as we grow the DAYBUE brand and advance our pipeline to bring new therapies to patients in need” said Catherine Owen Adams, Chief Executive Officer. 

Allyson brings over 20 years of pharmaceutical experience, including leadership roles at Pfizer and Bristol Myers Squibb (BMS). Most recently, she served as SVP and Business Unit Head, U.S. Oncology at BMS, where she played a pivotal role in overseeing two major acquisitions in the rare tumour space, leading to successful product launches and notable market share growth.

“I am excited to join Acadia Pharmaceuticals. Acadia has a strong commitment to patient care and innovation, and I look forward to working with the team to drive DAYBUE growth and prepare to bring new therapies to patients with rare diseases,” said Allyson McMillan-Youngblood. 

A graduate of Florida A&M University, Allyson is widely recognised for her ability to lead through change, champion inclusive leadership, and drive strategic, innovation-focused initiatives.